Amylyx Pharmaceuticals (AMLX) Return on Invested Capital (2023)
Historic Return on Invested Capital for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to 0.63%.
- Amylyx Pharmaceuticals' Return on Invested Capital rose 5700.0% to 0.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63%, marking a year-over-year increase of 5700.0%. This contributed to the annual value of 1.05% for FY2024, which is 11400.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Return on Invested Capital of 0.63% as of Q3 2025, which was up 5700.0% from 1.06% recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Return on Invested Capital registered a high of 0.08% during Q4 2023, and its lowest value of 1.74% during Q4 2024.
- For the 4-year period, Amylyx Pharmaceuticals' Return on Invested Capital averaged around 0.68%, with its median value being 0.62% (2025).
- Per our database at Business Quant, Amylyx Pharmaceuticals' Return on Invested Capital surged by 9200bps in 2023 and then plummeted by -18200bps in 2024.
- Amylyx Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.83% in 2022, then skyrocketed by 110bps to 0.08% in 2023, then tumbled by -2214bps to 1.74% in 2024, then soared by 64bps to 0.63% in 2025.
- Its Return on Invested Capital stands at 0.63% for Q3 2025, versus 1.06% for Q2 2025 and 1.25% for Q1 2025.